Skip to content Skip to footer
Subscribe Now
NEWS

Tanvex BioPharma Reports the US FDA’s Approval of Nypozi (Biosimilar, Neupogen)

Shots: The US FDA has granted BLA approval of Nypozi (TX01), biosimilar version of Amgen’s Neupogen Nypozi (TX01) is intended to reduce the incidence of infection among patients having non-myeloid malignancies undergoing chemotherapy that may reduce neutrophil count The company’s Nypozi was introduced across Canada in Jan 2024 Ref: Tanvex BioPharma | Image: Tanvex BioPharma | Press Release…
July 1, 2024

Read more

NEWS

Coherus BioSciences Launches an On Body Injector for the Administration of Udenyca (biosimiolar, pegfilgrastim) to Treat Non-Myeloid Malignancies

Shots:  The US FDA approved Udenyca Onbody earlier in Dec 2023, as an OBI device to administer Udenyca, a biosimilar of pegfilgrastim. The company has launched Udenyca in the US market for the treatment of patients with non-myeloid malignancies   Udencya is a leukocyte growth factor indicated to be administered the day after CT to lower the rate…
February 21, 2024

Read more